Shooting the Achilles heel of drug-resistant cancer


Cancer cells that develop resistance to drugs, pay a price for this, by simultaneously developing a new vulnerability.  If this acquired vulnerability can be identified, it may be exploited clinically. A team of cancer researchers, led by Rene Bernards of the Netherlands Cancer Institute and Oncode Institute, now exposed this acquired vulnerability in melanoma that has developed resistance to a targeted therapy with BRAF-inhibitors. The team then developed a new therapeutic strategy to selectively kill the drug-resistant cancer cells.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.